UPDATE: Synektik radiopharmaceuticals posts PLN 59.8 million in EBITDA from continuing operations in Q1

Revenues were up 12 pct year on year and amounted to PLN 228 million.

As reported, in Q1, sales of medical equipment, IT solutions and maintenance services increased by 12 pct year on year to PLN 214.1 million, while the segment's EBITDA increased to PLN 60.6 million.

The radiopharmaceuticals segment recorded a sales increase of 15 percent in the past quarter, to PLN 13.9 million, while the segment's EBITDA rose year-on-year from PLN 3.9 million to PLN 4.1 million.

The group increased its recurring revenues from the supply of consumables and accessories, the provision of services and the sale of radiopharmaceuticals under long-term agreements with customers by 32 percent to PLN 101.1 million.

As reported, in the first quarter of the 2025 financial year, the group secured contracts for the supply of medical equipment worth PLN 148 million, 30 percent higher than the value of contracts in the same period of 2024.

The group started the second quarter of the financial year with a backlog in equipment deliveries worth PLN 73.2 million, as well as open sales projects worth approximately PLN 166 million.

As reported, in the new year, the group is continuing the division process, under which research and development activities in the field of innovative radiopharmaceuticals, together with the cardio-marker project, will be spun off into the listed company Syn2bio.

According to the company's management board, the process of splitting the group and listing Syn2bio will be completed in the second quarter of this year.

The financial results for the first quarter of 2025/26 are presented below:

gaw/ nl/